SCHEMBL3657243

SCHEMBL3657243

OC(c1ccccn1)(c1ccccn1)C1CCNCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.57
KMT2A Q03164 4/20 0.57
LMNA P02545 1/20 0.57
CYP2D6 P10635 1/20 0.57
HRH1 P35367 1/20 0.57
SCN1A P35498 1/20 0.57
SCN2A Q99250 1/20 0.57
SCN3A Q9NY46 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PLD1 Q13393 1/20 0.38
CHRM3 P20309 1/20 0.37
NPY2R P49146 1/20 0.36
HTR1A P08908 2/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
SLC18A3 Q16572 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10733487 0.91 MEN1 (0.69) MEN1KMT2ALMNACYP2D6HRH1
SCHEMBL7436247 0.86 MEN1 (0.54) MEN1KMT2ALMNACYP2D6HRH1
SCHEMBL16291428 0.83 MEN1 (0.56) MEN1KMT2ALMNACYP2D6HRH1
SCHEMBL16291257 0.83 MEN1 (0.50) MEN1KMT2ALMNACYP2D6HRH1
Azacyclonol SCHEMBL1648657 0.74 HRH1 (0.93) MEN1KMT2ALMNACYP2D6HRH1
Hydrochloric Acid SCHEMBL11680499 0.73 NPY2R (0.46) MEN1KMT2ALMNACYP2D6HRH1
Azacyclonol SCHEMBL241817 0.73 HRH1 (1.00) MEN1KMT2ALMNACYP2D6HRH1
Azacyclonol SCHEMBL1890138 0.72 HRH1 (0.96) MEN1KMT2ALMNACYP2D6HRH1
Azacyclonol SCHEMBL6135637 0.72 HRH1 (0.96) MEN1KMT2ALMNACYP2D6HRH1
SCHEMBL18635455 0.71 SMN1; SMN2 (0.50) MEN1KMT2ASMN1; SMN2L3MBTL1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205561-A2 SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR Novartis Ag (CH) 2010-07-14 EP disclosed
WO-2009050197-A2 SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR NOVARTIS AG (CH) 2009-04-23 WO disclosed
WO-2009050197-A2 SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099199-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed
US-20090099199-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed
US-20090099199-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed
US-5063235-A 4-[(diaryl)hydromethyl]-1-piperidinealkanols and esters and carbamates thereof useful in the treatment of allergic disorders A. H. ROBINS COMPANY, INC. (US) 1991-11-05 US disclosed
US-4886794-A ANTIHISTAMINES, ANTIALLERGENS A. H. ROBINS COMPANY, INCORPORATED (US) 1989-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099199-A1 ORGANIC COMPOUNDS SLCO4C1, SLC10A6, SLCO1B1 MEN1 235/4885KMT2A 1654/4885LMNA 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.